XML 38 R24.htm IDEA: XBRL DOCUMENT v3.26.1

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):

Schedule of Cash and Cash Equivalents 

		December 31, 2025				December 31, 2024
Cash		$	5,600			$	9,591
Restricted cash included within prepaid expenses and other current assets			100				100
Restricted cash included within other noncurrent assets			119				118
Total cash and restricted cash as shown in the consolidated statements of cash flows		$	5,819			$	9,809

Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive

As the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because including them would have been antidilutive (in thousands):

Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive 

		2025				2024
		Year Ended December 31,
		2025				2024
Warrants for common stock			5,026				911
Employee stock options			278				77
Earnout shares			150				150
Restricted stock units			—				2
Contingently issuable warrants(1)			—				—
Total common stock equivalents			5,454				1,140

⁽¹⁾ The contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December 31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved in full and there were no contingently issuable warrants outstanding.

Schedule of Operating Segment

The following table presents selected financial information with respect to the Company’s single operating segment for the year ended December 31, 2025 and 2024:

Schedule of Operating Segment 

		2025				2024
		Year Ended December 31,
		2025				2024
OPERATING EXPENSES
Salaries and benefits		$	(9,561	)		$	(10,249	)
Insurance			(801	)			(1,442	)
Legal			(1,324	)			(1,951	)
Consulting			(2,059	)			(1,578	)
Rent and maintenance			(2,358	)			(2,136	)
Clinical & research and development			(1,760	)			(1,353	)
Depreciation expense			(386	)			(402	)
Change in fair value of other liabilities and derivatives			2				324
Other segment items (1)			(1,801	)			(3,408	)
Income tax provision			(15	)			(14	)
NET LOSS		$	(20,063	)		$	(22,209	)

⁽¹⁾ Other segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in Nova Cell, and other income, net.

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of cash, cash equivalent, and investment.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration